Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
GermanyIPO:
10 October 2019Website:
http://www.biontech.deNext earnings report:
07 August 2024Last dividends:
02 June 2022Next dividends:
N/APrice
after hours | 102 min agoAnalysts recommendations
Institutional Ownership
BNTX Latest News
Germany's BioNTech SE said in a regulatory filing on Monday the U.S. Food and Drug Administration has placed a partial clinical hold on an early-stage study of its experimental cancer drug.
COVID-19 vaccine maker BioNTech won up to $145 million in funding from a global coalition against infectious diseases to build a production network in African countries for messenger-RNA based shots.
H5N1 bird flu was detected this week in Michigan and Australia. It's the first detection in humans since March, when news of an outbreak in cattle emerged.
BioNTech's American depositary receipts (ADRs) experienced a slight decrease of less than 1% during intraday trading on Monday despite the company's ability to overcome losses and declining sales in the first quarter. The positive outlook provided for the year helped to offset these challenges.
The pharmaceutical company reports a loss of €1.31 per share in the first quarter, a significant change from the profit of €2.05 per share in the same period last year.
BioNTech (BNTX) is experiencing positive revisions to its earnings estimates and has a strong Zacks Earnings ESP as it approaches earnings season.
During BioNTech's (BNTX) first-quarter 2024 earnings call, investors will likely be interested in hearing about the progress of its pipeline development now that the pandemic has ended.
GlaxoSmithKline filed a lawsuit against Pfizer and BioNTech in a federal court in Delaware on Thursday, alleging that the companies have violated GSK patents associated with messenger RNA (mRNA) technology in their widely successful COVID-19 vaccines.
Best bargain stocks to buy is a simple but tricky concept. Whenever shares trade lower than an established multiple, whether that by earnings, sales, book or some other metric, there might be a reason for it.
As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market.
What type of business is BioNTech SE?
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
What sector is BioNTech SE in?
BioNTech SE is in the Healthcare sector
What industry is BioNTech SE in?
BioNTech SE is in the Biotechnology industry
What country is BioNTech SE from?
BioNTech SE is headquartered in Germany
When did BioNTech SE go public?
BioNTech SE initial public offering (IPO) was on 10 October 2019
What is BioNTech SE website?
https://www.biontech.de
Is BioNTech SE in the S&P 500?
No, BioNTech SE is not included in the S&P 500 index
Is BioNTech SE in the NASDAQ 100?
No, BioNTech SE is not included in the NASDAQ 100 index
Is BioNTech SE in the Dow Jones?
No, BioNTech SE is not included in the Dow Jones index
When does BioNTech SE report earnings?
The next expected earnings date for BioNTech SE is 07 August 2024